Curriculum Vitae

Personal information

Martina Schüssler-Lenz

Work experience

2005-2025 - Senior assessor, gene and cell therapies, Paul-Ehrlich Institut, Federal Institute for vaccines and biomedicines, Langen, Germany

2017-2023 - Chair, Committee for Advanced Therapies, European Medicines Agency, London and Amsterdam

2014-2017 - Vice chair, Committee for Advanced Therapies, European Medicines Agency, London, UK

1992-2005 - Medical Advisor, clinical program manager, anticancer drugs, Asta Medica AG, Frankfurt Germany and Baxter Oncology, Heidelberg, Germany

1989-1992 - Clinical fellow, department Internal Medicine III (Haematology/Oncology), Johannes Gutenberg Medical University, Mainz, Germany

Education and training

1988-1989 Postdoctoral research fellow, Instituto Municipal IMIM, Barcelona, Spain

1987-1988 Clinical fellow, Memorial Sloan Kettering Cancer Center, Immunology Service, New York, United States

1986-1988 Postdoctoral fellow, Memorial Sloan Kettering Cancer Center, Human Cancer Laboratory (Head Lloyd Old), New York, United States

1984-1986 Internship and clinical fellow, department internal medicine, hematology, oncology, Moabit Hospital, Berlin, Germany

1977-1983 Medical school, Johannes Gutenberg University, Mainz, Germany

Additional information

Publications

Flory E, Walter M, Closson-Carella V, Celis P, Schuessler-Lenz M, Reischl I: Medicinal products based on adeno-associated viral vectors: a regulatory perspective on the potential risk of insertion-mediated tumorigenesis. Hum Gene Ther, . 2025 Aug 11. doi: 10.1177/10430342251366314.

Schuessler-Lenz M, Hofner B. Arzneimittelzulassung im Bereich seltener Erkrankungen: die europäische regulatorische Perspektive am Beispiel der Gen- und Zelltherapeutika. [Marketing authorisation for rare diseases: The European regulatory perspective using the example of gene and cell therapies]. Z Evid Fortbild Qual Gesundhwes. 2024,189:73-81. doi: 10.1016/j.zefq.2024.08.007. Epub 2024 Sep 5.

Celis P, Farinelli G, Hidalgo-Simon A, Meij P, Tihaya M, Schuessler-Lenz M, Timón M.. EMA commentaries on the guideline on quality, non-clinical and clinical aspects of medicinal products containing genetically modified cells. Br J Clin Pharmacol, 2024 May;90(5):1203-1212. doi: 10.1111/bcp.16047. Epub 2024 Apr 2.

Anliker B, Childs L, Rau J, Renner M, Schüle S, Schuessler-Lenz M, Sebe A. Regulatory considerations for clinical trials applications with CRISPR-based medicinal products. CRISPR J, 2022, 5(3), 364-376.doi: 10.1089/crispr.2021.0148

Müller-Berghaus M, Sinan B, Schuessler-Lenz M. Kombinationstherapien in der Immunonkologie: Differenzierte regulatorische Herangehensweisen. Bundesgesundheitsbl. 2020; 63: 1388–1395. https://doi.org/10.1007/s00103-020-03228-2

Irene Papadouli, Jan Mueller‐Berghaus, Claire Beuneu, Sahra Ali, Benjamin Hofner, Frank Petavy, Kyriaki Tzogani, Anne Miermont, Koenraad Norga , Olga Kholmanskikh, Tim Leest, Martina Schuessler‐Lenz, Tomas Salmonson, Christian Gisselbrecht , Jordi Llinares Garcia, Francesco Pignatti. EMA Review of Axicabtagene Ciloleucel (Yescarta) for the Treatment of Diffuse Large B‐Cell Lymphoma. Oncologist 2020;25(10):894–902

Ali S, Kjeken R, Niederlaender C, Markey G, Saunders TS, Opsata M, Moltu K, Bremnes B, Grønevik E, Muusse M, Håkonsen GD, Skibeli V, Kalland ME, Wang I, Buajordet I, Urbaniak A, Johnston J, Rantell K, Kerwash E, Schuessler-Lenz M, Salmonson T, Bergh J, Gisselbrecht C, Tzogani K, Papadouli I, Pignatti F. The European Medicines Agency Review of Kymriah (Tisagenlecleucel) for the Treatment of Acute Lymphoblastic Leukemia and Diffuse Large B-Cell Lymphoma. Oncologist. 2020, 25(2): 321-327.

Schuessler-Lenz M, Enzmann H, Vamvakas S. Regulators' Advice Can Make a Difference: European Medicines Agency Approval of Zynteglo for Beta Thalassemia. Clin Pharmacol Ther. 2019 Nov 8. doi: 10.1002/cpt.1639.

Cathomen T, Schüle S, Schuessler-Lenz M, Abou-El-Enein M. The Human Genome Editing Race: Loosening Regulatory Standards for Commercial Advantage? Trends Biotechnol. 2019 Feb;37(2):120-123

Barkholt L, Voltz-Girolt C, Raine J, Salmonson T, Schuessler-Lenz M. Regulatory watch: European regulatory experience with advanced therapy medicinal products. Nat Rev Drug Discov. 2019 Jan;18 (1):8-9.

Krackhardt AM, Anliker B, Hildebrandt M, Bachmann M, Eichmüller SB, Nettelbeck DM, Renner M, Uharek L, Willimsky G, Schmitt M, Wels WS, Schuessler-Lenz M. Clinical translation and regulatory aspects of CAR/TCR-based adoptive cell therapies-the German Cancer Consortium approach. Cancer Immunol Immunother. 2018 Apr;67(4):513-523

Hartmann J, Schuessler-Lenz M, Bondanza A, Buchholz CJ. Clinical development of CAR T cells-challenges and opportunities in translating innovative treatment concepts. EMBO Mol Med. 2017 Sep;9(9):1183-1197

Schuessler-Lenz M, Beuneu C, Menezes-Ferreira M, Jekerle V, Bartunek J, Chamuleau S, Celis P, Doevendans P, O'Donovan M, Hill J, Hystad M, Jovinge S, Kyselovič J, Lipnik-Stangelj M, Maciulaitis R, Prasad K, Samuel A, Tenhunen O, Tonn T, Rosano G, Zeiher A, Salmikangas P. Cell-based therapies for cardiac repair: a meeting report on scientific observations and European regulatory viewpoints. Eur J Heart Fail. 2016 Feb;18(2):133-41.

Celis P, Ferry N, Hystad M, Schuessler-Lenz M, Doevendans PA, Flory E, Beuneu C, Reischl I, Salmikangas P. Advanced Therapy Medicinal Products: How to Bring Cell-Based Medicinal Products Successfully to the Market - Report from the CAT-DGTI-GSCN Workshop at the DGTI Annual Meeting 2014. Transfus Med Hemother. 2015 May;42(3):194-9.

Salmikangas P, Schuessler-Lenz M, Ruiz S, Celis P, Reischl I, Menezes-Ferreira M, Flory E, Renner M, Ferry N. Marketing Regulatory Oversight of Advanced Therapy Medicinal Products (ATMPs) in Europe: The EMA/CAT Perspective. Adv Exp Med Biol. 2015;871:103-30. Review.

Committee for Advanced Therapies (CAT); CAT Challenges with advanced therapy medicinal products and how to meet them. Nat Rev Drug Discov. 2010 Mar;9(3):195-201.

Schuessler-Lenz M, Schneider CK. Clinical trials with advanced therapy medicinal products]. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2010 Jan;53(1):68-74.

Copier J, Dalgleish AG, Britten CM, Finke LH, Gaudernack G, Gnjatic S, Kallen K, Kiessling R, Schuessler-Lenz M, Singh H, Talmadge J, Zwierzina H, Håkansson L. Improving the efficacy of cancer immunotherapy. Eur J Cancer 2009; 45:1424-31.

Sanzenbacher R, Dwenger A, Schuessler-Lenz M, Cichutek K, Flory E. European regulation tackles tissue engineering. Nat Biotechnol 2007; 25:1089-91.

Håkansson L, Dalgleish A, Kallen KJ, Schuessler-Lenz M. Vaccines: A rapidly evolving technology – Are the hurdles being addressed? Eur J Cancer 2007; Suppl 5:29-32.

van den Bent MJ, Grisold W, Frappaz D, Stupp R, Desir JP, Lesimple T, Dittrich C, de Jonge MJ, Brandes A, Frenay M, Carpentier AF, Chollet P, Oliveira J, Baron B, Lacombe D, Schuessler M, Fumoleau P; European Organization for Research and Treatment of Cancer New Drug Development Group; European Organization for Research and Treatment of Cancer Brain Tumor Group, and EORTC. Open label phase II study on glufosfamide administered as a 60-minute infusion every 3 weeks in recurrent glioblastoma multiforme. Ann Oncol 2003;14:1732-4.

Engel T, Klenner T, Niemeyer U, Peter G, Pohl J, Schuessler M, Schupke H, Voss A, Wiessler M. Glufosfamide. Drugs of the Future. 2000; 25:791-794.